Parisi Ludovica, Mockenhaupt Carolin, Rihs Silvia, Mansour Farah, Katsaros Christos, Degen Martin
Laboratory for Oral Molecular Biology, Department of Orthodontics and Dentofacial Orthopedics, University of Bern, Bern, Switzerland.
Front Oncol. 2022 Nov 15;12:1023072. doi: 10.3389/fonc.2022.1023072. eCollection 2022.
Interferon Regulatory Factor 6 (IRF6) and Grainyhead Like Transcription Factor 3 (GRHL3) are transcription factors that orchestrate gene regulatory networks required for the balance between keratinocyte differentiation and proliferation. Absence of either protein results in the lack of a normal stratified epidermis with keratinocytes failing to stop proliferating and to terminally differentiate. Numerous pathological variants within and have been identified in orofacial cleft-affected individuals and expression of the two transcription factors has been found to be often dysregulated in cancers. However, whether orofacial cleft-associated and variants in patients might also affect their cancer risk later in life, is not clear yet. The fact that the role of IRF6 and GRHL3 in cancer remains controversial makes this question even more challenging. Some studies identified IRF6 and GRHL3 as oncogenes, while others could attribute tumor suppressive functions to them. Trying to solve this apparent conundrum, we herein aimed to characterize IRF6 and GRHL3 function in various types of carcinomas. We screened multiple cancer and normal cell lines for their expression, and subsequently proceeded with functional assays in cancer cell lines. Our data uncovered consistent downregulation of IRF6 and in all types of carcinomas analyzed. Reduced levels of IRF6 and were found to be associated with several tumorigenic properties, such as enhanced cell proliferation, epithelial mesenchymal transition, migration and reduced differentiation capacity. Based on our findings, and can be considered as tumor suppressor genes in various carcinomas, which makes them potential common etiological factors for cancer and CLP in a fraction of CLP-affected patients.
干扰素调节因子6(IRF6)和颗粒头样转录因子3(GRHL3)是协调角质形成细胞分化与增殖平衡所需基因调控网络的转录因子。缺乏这两种蛋白质中的任何一种都会导致正常分层表皮缺失,角质形成细胞无法停止增殖并进行终末分化。在受口面部裂隙影响的个体中已鉴定出这两种基因内的众多病理变异,并且发现这两种转录因子的表达在癌症中常常失调。然而,患者中与口面部裂隙相关的这两种基因变异是否也会影响其晚年患癌风险,目前尚不清楚。IRF6和GRHL3在癌症中的作用仍存在争议这一事实使得这个问题更具挑战性。一些研究将IRF6和GRHL3鉴定为癌基因,而另一些研究则认为它们具有肿瘤抑制功能。为了解决这个明显的难题,我们在此旨在表征IRF6和GRHL3在各种类型癌症中的功能。我们筛选了多种癌细胞系和正常细胞系的表达情况,随后在癌细胞系中进行了功能测定。我们的数据揭示了在所分析的所有类型癌症中IRF6和GRHL3均一致下调。发现IRF6和GRHL3水平降低与多种致瘤特性相关,如细胞增殖增强、上皮-间质转化、迁移以及分化能力降低。基于我们的研究结果,IRF6和GRHL3可被视为各种癌症中的肿瘤抑制基因,这使得它们有可能成为一部分受口面部裂隙影响患者患癌和患唇腭裂的共同病因。